Overview

F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast Cancer

Status:
Completed

Trial end date:
2012-06-01

Target enrollment:

Participant gender:

Summary

RATIONALE: F511 cream may prevent or reduce palmar-plantar erythrodysesthesia in women receiving doxorubicin hydrochloride liposome for metastatic breast cancer. PURPOSE: This randomized phase III trial is studying F511 cream to see how well it works compared with a placebo cream in preventing palmar-plantar erythrodysesthesia in patients receiving doxorubicin hydrochloride liposome for metastatic breast cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Swiss Group for Clinical Cancer Research

Treatments:

Doxorubicin
Liposomal doxorubicin